Pioneering Acetazolamide as a Hormone-Responsive Neuroprotector: Unlocking Targeted Seizure Control in Catamenial Epilepsy Through Carbonic Anhydrase-Mediated Menstrual Cycle Modulation

Catamenial epilepsy affects as many as seven out of ten women with seizure disorders. It causes seizures linked to the menstrual cycle often resisting standard treatments. However, this pattern opens a chance for treatment using acetazolamide. This long-standing carbonic anhydrase inhibitor known for adjusting pH levels, shows promise as a neuroprotector that responds to hormonal changes. Acetazolamide helps restore GABA-A receptor function by lowering bicarbonate and increasing acid levels within cells. This fixes the imbalance caused by the reduction in allopregnanolone during the perimenstrual phase, the estrogen surge around ovulation that activates glutamate networks and the ongoing lack of neurosteroids in weak luteal phases. By targeting this metabolic process, it reduces excessive brain activity. Early studies on progesterone withdrawal and timing doses with the estrous cycle show an increase in seizure threshold stabilization of the δ-subunit, and a strong boost to the effects of neurosteroid treatments. Medical records and newer case studies report that over 60% of C1-pattern patients experience a reduction of perimenstrual seizures by at least half when given short and tolerant doses of 250-500 mg. Acetazolamide which is no longer viewed as just an outdated option from older research shows new promise in cycle-focused neurology. It is efficient alongside birth control, avoids impairing cognition, and opens the door to personalized treatments based on mid-luteal allopregnanolone levels and CA-II genetic markers. In this state, it calls for detailed trials tailored to different phases and advanced inhibitors to turn catamenial epilepsy from unpredictable distress into a controllable aspect of reproductive health.